Approved only for veterinary use as a sedative and painkiller, officials believe it is increasingly being mixed with other ...

Pregnant Oregonians need more addiction and mental health support — but the state’s network is fragile Substance use and ...

Okava Pharmaceuticals, a San Francisco based company, plans to introduce on Tuesday a new GLP-1 clinical weight loss study for cats. MEOW-1, as the study is called, will look to use OKV-119, a ...

Extended-release buprenorphine is approved as a once-monthly subcutaneous injection for the treatment of moderate-to-severe ...

A pharmaceutical company has begun testing the first GLP-1 weight-loss therapy designed specifically for cats. The implant, ...

San Francisco-based pharmaceutical company OKAVA is investigating an implant that slowly releases a GLP-1 medication for up ...

A clinical study into weight loss drugs for pets just launched, with results from the trial expected by next summer.

Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

Around 70% of Americans are obese or overweight. And their cats aren’t too far off. According to the Association for Pet ...

On this week's episode of The Vet Blast Podcast presented by dvm360, our host Adam Christman, DVM, MBA, welcomes Derek ...

Buprenorphine Lowers Opioid OD Risk, But Only If Taken As Directed Long-Term By Dennis Thompson HealthDay ReporterTHURSDAY, Nov. 20, 2025 (HealthDay News) — The opioid addiction medication ...

Among youth who initiated buprenorphine treatment for opioid use disorder, four patterns of buprenorphine use were identified, with the most common being discontinuation within 3 months. Low adherence ...